Heat Biologics, INC.: insider trades · United States · SEC (Form 4)

About Heat Biologics, INC.

HEAT BIOLOGICS, INC. is a U.S.-based biotechnology company that has been associated with the Nasdaq market and has undergone major corporate evolution in recent years, including name changes and strategic repositioning. Its historical identity was Heat Biologics, Inc.; it later became NightHawk Biosciences and then Scorpius Holdings, reflecting a broader shift from a pure immuno-oncology developer toward a more vertically integrated life-sciences platform. The company’s roots date to 2008, and its principal headquarters have been in Morrisville, North Carolina, United States. For investors, this is a classic small-cap biotech profile: high scientific optionality, meaningful execution risk, and a continuing dependence on capital markets. Originally, the company was built around proprietary therapeutic vaccine platforms, including ImPACT and ComPACT, designed to activate T-cells against defined cancer targets. Over time, it expanded its ambitions into broader immunotherapy, biodefense, biomanufacturing, and life-sciences services through subsidiary structures and asset additions. This matters from a competitive standpoint: Heat has generally not tried to compete as a broad commercial pharmaceutical company, but rather as a niche platform player seeking differentiation through patented biologic approaches and vertically integrated capabilities. In biotechnology, that can be a source of upside if a program advances, but it also means the business model is highly sensitive to clinical data, regulatory milestones, and financing events. Among the best-known development programs in its history are HS-110, an off-the-shelf cell-based immunotherapy candidate, and PTX-35, an immunomodulatory antibody program. The company has also highlighted biodefense-related assets and manufacturing capabilities, showing an effort to broaden beyond early-stage oncology. From an investor perspective, these programs provide multiple shots on goal, but they also increase complexity and make the equity story difficult to value on conventional earnings metrics. The appropriate framework is pipeline optionality, not near-term profitability. Geographically, the business remains anchored in the United States, with the corporate base in North Carolina and prior disclosures indicating international subsidiaries in Germany and Australia. Because the company is a U.S.-listed issuer on Nasdaq, the listing venue and country are important context for liquidity, disclosure standards, and market perception. For French-speaking investors, that also signals a U.S. small-cap biotech name that trades under the scrutiny of SEC reporting and insider-trading disclosures such as Form 4 filings. Recent corporate developments have been significant. The company completed a name change from Heat Biologics to NightHawk Biosciences in 2022, then announced another rebrand to Scorpius Holdings in 2024. SEC filings and company communications also indicate ongoing portfolio reshaping, balance-sheet management, and capital raising, including equity issuance and debt repayment. In practical terms, the recent history suggests a company actively trying to refine its strategic focus and funding structure rather than a stable, mature commercial biotech. That makes it a speculative investment case best evaluated through clinical progress, asset monetization, and dilution risk rather than through traditional revenue-based valuation.